GuidelineThe American journal of gastroenterology2013
Clinical guideline: management of gastroparesis.
Guideline in The American journal of gastroenterology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 7 registered trials, which are not on this map. Cited by 425 papers, 16 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective, Observational Study of the PPI Non-responder
Long-term Results of Per-oral Pyloromyotomy for Refractory Gastroparesis
Use of Endoscopic Functional Lumen Imaging Probe (EndoFLIP) and Antroduodenal Manometry (ADM) in Predicting Clinical Response to Gastric Peroral Endoscopic Myotomy (G-POEM): A Pilot Study
AnX/Ankon Navicam Magnetically Controlled Capsule Endoscopy Feasibility Study in Gastric Motility
High Resolution Electrogastrography (HR-EGG) Assessment in Medically Refractory Gastroparesis
Gastroparesis Registry 4 (GpR4): Improving the Understanding of Gastroparesis and Functional Dyspepsia
GpCRC Pediatric Gastroparesis Registry 2: Characterization and Clinical Course of Symptoms and Gastric Emptying in Pediatric, Adolescent, and Young Adult Participants With Symptoms of Gastroparesis
Who cites it
425 citing papers in PubMed, 16 syntheses or guidelines pooled it, 1,127 citations in OpenAlex.
- Symptoms and clinical outcomes of gastric electrical stimulation in treatment-resistant gastroparesis: a systematic review across short- and long-term follow-up.Surgical endoscopy · 2026Pooled it
- Meta-Analysis: Prevalence and Incidence of Gastroparesis Following Lung or Heart Transplantation.Alimentary pharmacology & therapeutics · 2026Pooled it
- Pooled it
- Cisapride for gastric emptying in diabetic patients: a meta-analysis on its efficacy and safety.Hormones (Athens, Greece) · 2025Pooled it
- Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement.British journal of anaesthesia · 2025Pooled it
- Risk factors for enteral feeding intolerance in critically ill patients: an updated systematic review and meta-analysis.BMC gastroenterology · 2025Pooled it
- European Guideline on Chronic Nausea and Vomiting-A UEG and ESNM Consensus for Clinical Management.United European gastroenterology journal · 2025Guideline
- A bibliometric analysis of diabetic gastroparesis from 1979 to 2024.Frontiers in medicine · 2024Pooled it
- Invasive acupuncture for gastroparesis after thoracic or abdominal surgery: a systematic review and meta-analysis.BMJ open · 2023Pooled it
- Risk of Adverse Events Associated with Domperidone and Metoclopramide in Gastroparesis: Systematic Review and Meta-analysis.Drugs in R&D · 2023Pooled it
- Systematic review of small intestine pacing parameters for modulation of gut function.Neurogastroenterology and motility · 2023Pooled it
- Pooled it
- Pooled it
- Guideline
- Guideline
- European guideline on indications, performance and clinical impact ofUnited European gastroenterology journal · 2021Guideline
- Results of a Phase 1 Study Assessing the Effect of CIN-102, a Novel Formulation of the Dopamine Receptor Antagonist Domperidone Designed to Treat Gastroparesis, on Cardiac Repolarization in Healthy Volunteers.Clinical pharmacology in drug development · 2026Trial
- Mosapride versus Metoclopramide in Critically Ill Patients with Enteral Feeding Intolerance: A Randomized, Double-Blinded Comparison.Drug design, development and therapy · 2026Trial
- Transcutaneous Electrical Acustimulation Improves Gastroparesis Symptoms and Ameliorates Gastric Pace-Making Activity in Patients With Diabetic Gastroparesis.Neurogastroenterology and motility · 2025Trial
- Disentangling the links between gastric emptying and binge eatingPsychological medicine · 2023Trial
365 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
Abstract
This guideline presents recommendations for the evaluation and management of patients with gastroparesis. Gastroparesis is identified in clinical practice through the recognition of the clinical symptoms and documentation of delayed gastric emptying. Symptoms from gastroparesis include nausea, vomiting, early satiety, postprandial fullness, bloating, and upper abdominal pain. Management of gastroparesis should include assessment and correction of nutritional state, relief of symptoms, improvement of gastric emptying and, in diabetics, glycemic control. Patient nutritional state should be managed by oral dietary modifications. If oral intake is not adequate, then enteral nutrition via jejunostomy tube needs to be considered. Parenteral nutrition is rarely required when hydration and nutritional state cannot be maintained. Medical treatment entails use of prokinetic and antiemetic therapies. Current approved treatment options, including metoclopramide and gastric electrical stimulation (GES, approved on a humanitarian device exemption), do not adequately address clinical need. Antiemetics have not been specifically tested in gastroparesis, but they may relieve nausea and vomiting. Other medications aimed at symptom relief include unapproved medications or off-label indications, and include domperidone, erythromycin (primarily over a short term), and centrally acting antidepressants used as symptom modulators. GES may relieve symptoms, including weekly vomiting frequency, and the need for nutritional supplementation, based on open-label studies. Second-line approaches include venting gastrostomy or feeding jejunostomy; intrapyloric botulinum toxin injection was not effective in randomized controlled trials. Most of these treatments are based on open-label treatment trials and small numbers. Partial gastrectomy and pyloroplasty should be used rarely, only in carefully selected patients. Attention should be given to the development of new effective therapies for symptomatic control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.